{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:44:33Z","timestamp":1785793473417,"version":"3.56.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijgc.2026.104790","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:36:50Z","timestamp":1780727810000},"page":"104790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of stereotactic ablative body radiotherapy for treatment of oligometastatic gynecological cancers: a narrative review"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2387-252X","authenticated-orcid":false,"given":"Fergus","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-0747","authenticated-orcid":false,"given":"Krystel","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-7326","authenticated-orcid":false,"given":"Ming-Yin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.104790_bib1","unstructured":"Cancer data in Australia. Australian Institute of Health and Welfare. Accessed May 19, 2026. https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia."},{"issue":"10125","key":"10.1016\/j.ijgc.2026.104790_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104790_bib3","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1634\/theoncologist.2016-0144","article-title":"First-line chemotherapy for ovarian cancer: inferences from recent studies","volume":"21","author":"Rose","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104790_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ygyno.2012.04.012","article-title":"Centralisation of services for gynaecological cancers \u2014 a Cochrane systematic review","volume":"126","author":"Woo","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104790_bib5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/cancers16040770","article-title":"Recent therapeutic advances in gynecologic oncology: a review","volume":"16","author":"Wilson","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104790_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104790_bib7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.104790_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2020.10.037","article-title":"Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network","volume":"155","author":"Chopra","year":"2021","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104790_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104119","article-title":"Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence","volume":"10","author":"Loverro","year":"2025","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104790_bib10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","volume":"32","author":"Palluzzi","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104790_bib11","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104790_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fonc.2012.00181","article-title":"Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies","volume":"2","author":"Kunos","year":"2012","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104790_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2024.09.036","article-title":"Stereotactic ablative radiation therapy for oligometastatic ovarian cancer lymph node disease: the MITO-RT3\/RAD phase II trial","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijgc.2026.104790_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijgc.2026.104790_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.572564","article-title":"Stereotactic body radiation therapy: a versatile, well-tolerated, and effective treatment option for extra-cranial metastases from primary ovarian and uterine cancer","volume":"10","author":"Aghdam","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104790_bib16","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1007\/s00432-021-03802-4","article-title":"The use of SBRT in the management of oligometastatic gynecological cancer: report of promising results in terms of tolerability and clinical outcomes","volume":"147","author":"Cuccia","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104790_bib17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaoncol.2024.1796","article-title":"Stereotactic ablative radiotherapy for gynecological oligometastatic and oligoprogessive tumors","volume":"10","author":"Donovan","year":"2024","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104790_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/ijgc-2019-001115","article-title":"Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis","volume":"30","author":"Onal","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104790_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ygyno.2020.10.001","article-title":"Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers","volume":"159","author":"Reshko","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104790_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/IGC.0000000000000885","article-title":"Clinical outcomes of stereotactic body radiotherapy in oligometastatic gynecological cancer","volume":"27","author":"Laliscia","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104790_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/IGC.0000000000000869","article-title":"Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies","volume":"27","author":"Mesko","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104790_bib22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13014-020-01564-w","article-title":"Stereotactic body radiation therapy in the treatment of ovarian cancer","volume":"15","author":"Kowalchuk","year":"2020","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104790_bib23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104790_bib24","first-page":"198","article-title":"Management of recurrent epithelial ovarian cancer","volume":"3","author":"Vargas-Hern\u00e1ndez","year":"2013","journal-title":"Gland Surg"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104790_bib25","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ijgc-2024-005361","article-title":"Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)","volume":"34","author":"Durante","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104790_bib26","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/IGC.0000000000001324","article-title":"Stereotactic body radiation therapy in oligometastatic ovarian cancer: a promising therapeutic approach","volume":"28","author":"Iftode","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104790_bib27","first-page":"5103","article-title":"Stereotactic body radiotherapy for recurrent or oligometastatic uterine cervix cancer: a cooperative study of the Korean radiation oncology group (KROG 14-11)","volume":"35","author":"Park","year":"2015","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104790_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ajco.13159","article-title":"Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer","volume":"15","author":"Hou","year":"2019","journal-title":"Asia Pac J Clin Oncol."},{"issue":"10421","key":"10.1016\/j.ijgc.2026.104790_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104790_bib30","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with Cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104790_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijrobp.2025.05.003","article-title":"Atezolizumab and stereotactic body radiation in metastatic, recurrent, or persistent cervical cancer: results from a phase 2 multi-institutional study","volume":"125","author":"Ahmed","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104790_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","article-title":"Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021","volume":"18","author":"Li","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104790_bib33","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"8-9","key":"10.1016\/j.ijgc.2026.104790_bib34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/07357907.2020.1817483","article-title":"Stereotactic body radiation therapy in oligometastatic uterine cancer: clinical outcomes and toxicity","volume":"38","author":"Reddy","year":"2020","journal-title":"Cancer Investig"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104790_bib35","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104790_bib36","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1016\/j.ijgc.2026.104790_bib37","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104790_bib38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clon.2017.01.009","article-title":"The role of stereotactic ablative body radiotherapy in gynaecological cancers: a systematic review","volume":"29","author":"Mendez","year":"2017","journal-title":"Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104790_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/jpm13020229","article-title":"Clinical outcomes of stereotactic body radiotherapy (SBRT) for oligometastatic patients with lymph node metastases from gynecological cancers","volume":"13","author":"Facondo","year":"2023","journal-title":"J Pers Med"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104790_bib40","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.rpor.2014.10.004","article-title":"Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?","volume":"20","author":"Jereczek-Fossa","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104790_bib41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13014-018-1096-9","article-title":"A phase I dose-escalation trial of Stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)","volume":"13","author":"Mercier","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijgc.2026.104790_bib42","article-title":"Cost effectiveness of immunotherapy combination therapies for endometrial cancer","volume":"52","author":"Benjamin","year":"2024","journal-title":"Gynecol Oncol Rep"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104790_bib43","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3390\/jcm15041657","article-title":"Outcomes of first-line PARP inhibitor therapy in ovarian cancer: a multicenter retrospective analysis","volume":"15","author":"Koksal","year":"2026","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104790_bib44","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ygyno.2020.12.015","article-title":"Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients","volume":"160","author":"Liang","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104790_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.49685","article-title":"Stereotactic body radiotherapy without systemic therapy for oligometastatic cancer: a systematic review and meta-analysis","volume":"8","author":"Willmann","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2600321X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2600321X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:48:36Z","timestamp":1785790116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2600321X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1048891X2600321X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104790","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of stereotactic ablative body radiotherapy for treatment of oligometastatic gynecological cancers: a narrative review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104790"}}